Among the retrieved clinicopathological factors (including Fib status) of all patients, invasive ductal histology (HR = 2.093), tumour size > 5 cm (HR = 1.452), lymph node involvement (HR = 1.742), specific molecular subtypes (HR*(+)HER2(+) vs HR*(+)HER2(−), HR = 1.529; HR*(−)HER2(+) vs HR*(+)HER2(−), HR = 2.195; HR*(−)HER2(−) vs HR*(+)HER2(−), HR = 2.843) and non-pCR (HR = 1.794) were associated with worse RFS outcomes (all P <  0.05, Table 6). The gene discussed is ERBB2; the disease is neoplasm.